This trial is testing a new combination therapy for pancreatic, lung, and colon cancers that have spread and become resistant to treatment.
10 Primary · 6 Secondary · Reporting Duration: Up to 4 years
Experimental Treatment
53 Total Participants · 1 Treatment Group
Primary Treatment: Durvalumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: